Relmada Therapeutics Inc (RLMD) 3.9200 $RLMD
Relmada Therapeutics Announces Management Promotions
PR Newswire - Mon Oct 05, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today two management promotions. Richard M. Mangano, Ph.D. has been promoted to chief scientific officer and Lisa Nolan, Ph.D. has been promoted to the newly created position of chief business officer. Both professionals will take on a broader range of clinical and business development activities at Relmada as the company continues to advance its pipeline of innovative therapies for the treatment of chronic pain.
Relmada Therapeutics to Present at Aegis 2015 Growth Conference
PR Newswire - Fri Oct 02, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the company will present at the Aegis 2015 Growth Conference being held October 7-9, 2015 at The Encore Wynn in Las Vegas.
Relmada Therapeutics to Present at Ladenburg Thalmann 2015 Healthcare Conference
PR Newswire - Wed Sep 23, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that Sergio Traversa, chief executive officer, will present at the Ladenburg Thalmann 2015 Healthcare Conference at the Sofitel Hotel in New York. The presentation is scheduled to take place at 3:00 pm Eastern Time on Tuesday, September 29, 2015.
Relmada Therapeutics Announces Issuance of U.S. Patent Covering SECUREL(TM) - an Abuse-Deterrent, Extended-Release, Technology Platform for Opioids
PR Newswire - Wed Sep 09, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that U.S. Patent No. 9,125,833 was issued by the U.S. Patent and Trademark Office (USPTO) for its patent application entitled, "Multimodal abuse resistant and extended release opioid formulations." The issued patent covers the SECUREL technology platform and Relmada's lead product candidate, LevoCap ER (REL-1015, levorphanol extended-release, abuse deterrent capsules) as well as providing additional coverage for multiple opioid molecules that are prone to abuse.
Relmada Therapeutics passes Health Canada's clearance to begin multiple ascending dose study with d-Methadone in the first half of 2016
M2 - Tue Aug 18, 3:42AM CDT
Pharmaceutical company Relmada Therapeutics (Other OTC:RLMD) disclosed on Monday the receipt of a No Objection Letter (NOL) from Health Canada to conduct a multiple ascending dose (MAD) clinical study with d-Methadone (REL-1017 dextromethadone) for the treatment of neuropathic pain.
Relmada Therapeutics Receives Health Canada Clearance to Commence Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist
PR Newswire - Mon Aug 17, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has received a No Objection Letter (NOL) from Health Canada to conduct a multiple ascending dose (MAD) clinical study with d-Methadone (REL-1017 dextromethadone), its novel, N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain.
Relmada Therapeutics Announces Launch of New Website and Corporate Communication Channels
PR Newswire - Wed Aug 12, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD; RLMDD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today the launch of a newly formatted website featuring enhanced and readily accessible information for shareholders and other interested parties, improved navigation, and the launch of several online corporate communication channels. The new website can be accessed at www.relmada.com.
Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
PR Newswire - Mon Aug 10, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that its Board of Directors has approved a 1-for-5 reverse stock split of the company's authorized, issued, and outstanding common stock in preparation for its proposed listing of its common stock on the NASDAQ Capital Market. The reverse stock split will become effective with the Financial Industry Regulatory Authority (FINRA) and in the marketplace at the open of business on August 12, 2015, whereupon the shares of common stock will begin trading on a split-adjusted basis.
Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone
PR Newswire - Mon Jul 27, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it has filed a Clinical Trial Application (CTA) with Heath Canada to conduct a multiple ascending dose (MAD) clinical study with d-Methadone (dextromethadone, REL-1017), its novel, N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain.
Relmada Therapeutics hires Charles J. Casamento to board
M2 - Fri Jul 17, 5:29AM CDT
Novel therapies company Relmada Therapeutics (OtherOTC:RLMD) revealed on Thursday the election of Charles J. Casamento to its board of directors.
Relmada Therapeutics Appoints Charles J. Casamento to Its Board of Directors
PR Newswire - Thu Jul 16, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today Charles J. Casamento has joined the company's board of directors, completing the slate of three independent directors. Mr. Casamento will also serve as chairman of the audit committee for Relmada Therapeutics.
Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark
PR Newswire - Mon Jun 29, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that patient enrollment in its proof-of-concept pharmacokinetic study with novel formulations of oral, enteric-coated buprenorphine (collectively BuTab, or REL-1028) being developed for both chronic pain and opioid dependence indications has reached the halfway point. Consistent with prior guidance, the company anticipates reporting top-line results in the second half of 2015.
Relmada Therapeutics to Present at 2015 BIO International Convention
PR Newswire - Mon Jun 15, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that Sergio Traversa, chief executive officer, will present an overview of the Company at the BIO Business Forum, part of the 2015 BIO International Convention, on Wednesday, June 17, 2015, at 2:30 p.m. ET, at the Pennsylvania Convention Center, in presentation room Theater 2, Philadelphia, PA.
Postherpetic Neuralgia - Pipeline Review, H1 2015
M2 - Thu Jun 11, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hg24hw/postherpetic) has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Aestus Therapeutics - Allergan - Arcion Therapeutics - Astellas Pharma - Daewoong Pharmaceutical - Daiichi Sankyo - Immune Pharmaceuticals - Intellipharmaceutics International - Merck & Co. - NeurAxon - Nuvo Research - Pfizer - Phosphagenics - Purdue Pharma - Relmada Therapeutics - Scilex Pharmaceuticals - Spinifex Pharmaceuticals - Teva Pharmaceutical Industries - Winston Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/hg...stherpetic
AGN: 274.84 (-1.32), IPCI: 1.80 (-0.05), MRK: 50.95 (-0.07), TEVA: 58.96 (-0.28), IMNP: 1.28 (+0.02)
Relmada Therapeutics Successfully Completes Phase 1 Single Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone
PR Newswire - Wed Jun 10, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has successfully completed a Phase 1 single ascending dose (SAD) clinical study with d-Methadone (dextromethadone, REL-1017), its novel, N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain.
Global Opium (Opioid) Addiction Pipeline Review, H1 2015 - 15 Companies & 20 Drug Profiles
M2 - Wed Jun 10, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhxtt9/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acura Pharmaceuticals, Inc. - Alkermes Plc - BioDelivery Sciences International, Inc. - Camurus AB - Celtic Pharmaceutical Holdings L.P. - D&A Pharma SAS - Foresee Pharmaceuticals, LLC - Heron Therapeutics, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Omeros Corporation - Pfizer Inc. - Relmada Therapeutics, Inc. - Titan Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. Drug Profiles - (buprenorphine hydrochloride naloxone hydrochloride) - Buprenorphine Hemiadipate Hydrochloride - buprenorphine hydrochloride - buprenorphine hydrochloride depot - buprenorphine hydrochloride ER - buprenorphine hydrochloride long acting - buprenorphine hydrochloride SR - cannabidiol - FP-004 - MAL - methadone IR - naltrexone - naltrexone - OMS-405 - OMS-527 - PF-5006739 - samidorphan - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - TA-CD - Vaccine for Opium Addiction For more information visit http://www.researchandmarkets.com/research/hh...ium_opioid
BDSI: 6.74 (+0.22), INSY: 25.65 (+0.64), HRTX: 25.72 (-0.93), PFE: 33.24 (+0.15), ALKS: 60.82 (+0.92), ACUR: 2.65 (+0.14), OMER: 12.66 (+0.58)
Relmada Therapeutics, Inc. - Product Pipeline Review - 2014
M2 - Thu May 28, 6:31AM CDT
Product Pipeline Review - 2014
Relmada Therapeutics to Present at the 2015 LD Micro Invitational Conference
PR Newswire - Wed May 27, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the 2015 LD Micro Invitational Conference on Monday, June 1, 2015 at the Luxe Sunset Hotel in Bel Air, California.
Relmada Therapeutics to Present at the 2015 Marcum MicroCap Conference
PR Newswire - Tue May 19, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the 2015 Marcum MicroCap Conference on Thursday, May 28, 2015 in New York City at the Grand Hyatt Hotel.
Addiction Pipeline Review 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mhcllx/addiction) has announced the addition of the "Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Acura Pharmaceuticals, Inc. - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astraea Therapeutics, LLC - AstraZeneca PLC - Beech Tree Labs, Inc. - BioDelivery Sciences International, Inc. - Bionex Pharmaceuticals LLC - Eli Lilly and Company - Embera NeuroTherapeutics, Inc. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - FORUM Pharmaceuticals Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Grunenthal GmbH - Heptares Therapeutics Ltd. - Immunovaccine, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Invion Limited - Johnson & Johnson - Pfizer Inc. - Relmada Therapeutics, Inc. - Rottapharm SpA - Royalty Pharma - Selecta Biosciences, Inc. - SK Biopharmaceuticals Co., Ltd. - Sun Pharma Advanced Research Company Ltd. - Targacept, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mhcllx/addiction
BDSI: 6.74 (+0.22), PFE: 33.24 (+0.15), LLY: 86.14 (+2.37), GSK: 40.22 (+0.06), ACUR: 2.65 (+0.14), JNJ: 95.37 (+0.29), INSY: 25.65 (+0.64), TRGT: 0.96 (-1.25), GILD: 100.65 (-0.16), AZN: 32.23 (-0.16), ABBV: 55.64 (-0.40), ARNA: 2.19 (+0.14)
Relmada Therapeutics Announces Management Promotions
PR Newswire - Mon Oct 05, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today two management promotions. Richard M. Mangano, Ph.D. has been promoted to chief scientific officer and Lisa Nolan, Ph.D. has been promoted to the newly created position of chief business officer. Both professionals will take on a broader range of clinical and business development activities at Relmada as the company continues to advance its pipeline of innovative therapies for the treatment of chronic pain.
Relmada Therapeutics to Present at Aegis 2015 Growth Conference
PR Newswire - Fri Oct 02, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that the company will present at the Aegis 2015 Growth Conference being held October 7-9, 2015 at The Encore Wynn in Las Vegas.
Relmada Therapeutics to Present at Ladenburg Thalmann 2015 Healthcare Conference
PR Newswire - Wed Sep 23, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that Sergio Traversa, chief executive officer, will present at the Ladenburg Thalmann 2015 Healthcare Conference at the Sofitel Hotel in New York. The presentation is scheduled to take place at 3:00 pm Eastern Time on Tuesday, September 29, 2015.
Relmada Therapeutics Announces Issuance of U.S. Patent Covering SECUREL(TM) - an Abuse-Deterrent, Extended-Release, Technology Platform for Opioids
PR Newswire - Wed Sep 09, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that U.S. Patent No. 9,125,833 was issued by the U.S. Patent and Trademark Office (USPTO) for its patent application entitled, "Multimodal abuse resistant and extended release opioid formulations." The issued patent covers the SECUREL technology platform and Relmada's lead product candidate, LevoCap ER (REL-1015, levorphanol extended-release, abuse deterrent capsules) as well as providing additional coverage for multiple opioid molecules that are prone to abuse.
Relmada Therapeutics passes Health Canada's clearance to begin multiple ascending dose study with d-Methadone in the first half of 2016
M2 - Tue Aug 18, 3:42AM CDT
Pharmaceutical company Relmada Therapeutics (Other OTC:RLMD) disclosed on Monday the receipt of a No Objection Letter (NOL) from Health Canada to conduct a multiple ascending dose (MAD) clinical study with d-Methadone (REL-1017 dextromethadone) for the treatment of neuropathic pain.
Relmada Therapeutics Receives Health Canada Clearance to Commence Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist
PR Newswire - Mon Aug 17, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has received a No Objection Letter (NOL) from Health Canada to conduct a multiple ascending dose (MAD) clinical study with d-Methadone (REL-1017 dextromethadone), its novel, N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain.
Relmada Therapeutics Announces Launch of New Website and Corporate Communication Channels
PR Newswire - Wed Aug 12, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD; RLMDD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today the launch of a newly formatted website featuring enhanced and readily accessible information for shareholders and other interested parties, improved navigation, and the launch of several online corporate communication channels. The new website can be accessed at www.relmada.com.
Relmada Therapeutics Announces Reverse Stock Split in Preparation for Proposed Uplisting to NASDAQ Capital Market
PR Newswire - Mon Aug 10, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that its Board of Directors has approved a 1-for-5 reverse stock split of the company's authorized, issued, and outstanding common stock in preparation for its proposed listing of its common stock on the NASDAQ Capital Market. The reverse stock split will become effective with the Financial Industry Regulatory Authority (FINRA) and in the marketplace at the open of business on August 12, 2015, whereupon the shares of common stock will begin trading on a split-adjusted basis.
Relmada Therapeutics Announces Filing of Clinical Trial Application in Canada for Multiple Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone
PR Newswire - Mon Jul 27, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, today announced that it has filed a Clinical Trial Application (CTA) with Heath Canada to conduct a multiple ascending dose (MAD) clinical study with d-Methadone (dextromethadone, REL-1017), its novel, N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain.
Relmada Therapeutics hires Charles J. Casamento to board
M2 - Fri Jul 17, 5:29AM CDT
Novel therapies company Relmada Therapeutics (OtherOTC:RLMD) revealed on Thursday the election of Charles J. Casamento to its board of directors.
Relmada Therapeutics Appoints Charles J. Casamento to Its Board of Directors
PR Newswire - Thu Jul 16, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today Charles J. Casamento has joined the company's board of directors, completing the slate of three independent directors. Mr. Casamento will also serve as chairman of the audit committee for Relmada Therapeutics.
Enrollment in Relmada Therapeutics' Proof-of-Concept Clinical Study for Novel Oral Formulations of Buprenorphine Reaches Halfway Mark
PR Newswire - Mon Jun 29, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that patient enrollment in its proof-of-concept pharmacokinetic study with novel formulations of oral, enteric-coated buprenorphine (collectively BuTab, or REL-1028) being developed for both chronic pain and opioid dependence indications has reached the halfway point. Consistent with prior guidance, the company anticipates reporting top-line results in the second half of 2015.
Relmada Therapeutics to Present at 2015 BIO International Convention
PR Newswire - Mon Jun 15, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that Sergio Traversa, chief executive officer, will present an overview of the Company at the BIO Business Forum, part of the 2015 BIO International Convention, on Wednesday, June 17, 2015, at 2:30 p.m. ET, at the Pennsylvania Convention Center, in presentation room Theater 2, Philadelphia, PA.
Postherpetic Neuralgia - Pipeline Review, H1 2015
M2 - Thu Jun 11, 4:59AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hg24hw/postherpetic) has announced the addition of the "Postherpetic Neuralgia - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Postherpetic Neuralgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Postherpetic Neuralgia and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Companies Mentioned - Aestus Therapeutics - Allergan - Arcion Therapeutics - Astellas Pharma - Daewoong Pharmaceutical - Daiichi Sankyo - Immune Pharmaceuticals - Intellipharmaceutics International - Merck & Co. - NeurAxon - Nuvo Research - Pfizer - Phosphagenics - Purdue Pharma - Relmada Therapeutics - Scilex Pharmaceuticals - Spinifex Pharmaceuticals - Teva Pharmaceutical Industries - Winston Pharmaceuticals For more information visit http://www.researchandmarkets.com/research/hg...stherpetic
AGN: 274.84 (-1.32), IPCI: 1.80 (-0.05), MRK: 50.95 (-0.07), TEVA: 58.96 (-0.28), IMNP: 1.28 (+0.02)
Relmada Therapeutics Successfully Completes Phase 1 Single Ascending Dose Study with Promising NMDA Receptor Antagonist d-Methadone
PR Newswire - Wed Jun 10, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it has successfully completed a Phase 1 single ascending dose (SAD) clinical study with d-Methadone (dextromethadone, REL-1017), its novel, N-methyl-D-aspartate (NMDA) receptor antagonist being developed for the treatment of neuropathic pain.
Global Opium (Opioid) Addiction Pipeline Review, H1 2015 - 15 Companies & 20 Drug Profiles
M2 - Wed Jun 10, 6:30AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hhxtt9/opium_opioid) has announced the addition of the "Opium (Opioid) Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Opium (Opioid) Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Opium (Opioid) Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Acura Pharmaceuticals, Inc. - Alkermes Plc - BioDelivery Sciences International, Inc. - Camurus AB - Celtic Pharmaceutical Holdings L.P. - D&A Pharma SAS - Foresee Pharmaceuticals, LLC - Heron Therapeutics, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Omeros Corporation - Pfizer Inc. - Relmada Therapeutics, Inc. - Titan Pharmaceuticals, Inc. - Zynerba Pharmaceuticals, Inc. Drug Profiles - (buprenorphine hydrochloride naloxone hydrochloride) - Buprenorphine Hemiadipate Hydrochloride - buprenorphine hydrochloride - buprenorphine hydrochloride depot - buprenorphine hydrochloride ER - buprenorphine hydrochloride long acting - buprenorphine hydrochloride SR - cannabidiol - FP-004 - MAL - methadone IR - naltrexone - naltrexone - OMS-405 - OMS-527 - PF-5006739 - samidorphan - Synthetic Peptides to Inhibit Mu Opioid, Delta Opioid and MRP-1 for Oncology and Morphine Addiction - TA-CD - Vaccine for Opium Addiction For more information visit http://www.researchandmarkets.com/research/hh...ium_opioid
BDSI: 6.74 (+0.22), INSY: 25.65 (+0.64), HRTX: 25.72 (-0.93), PFE: 33.24 (+0.15), ALKS: 60.82 (+0.92), ACUR: 2.65 (+0.14), OMER: 12.66 (+0.58)
Relmada Therapeutics, Inc. - Product Pipeline Review - 2014
M2 - Thu May 28, 6:31AM CDT
Product Pipeline Review - 2014
Relmada Therapeutics to Present at the 2015 LD Micro Invitational Conference
PR Newswire - Wed May 27, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the 2015 LD Micro Invitational Conference on Monday, June 1, 2015 at the Luxe Sunset Hotel in Bel Air, California.
Relmada Therapeutics to Present at the 2015 Marcum MicroCap Conference
PR Newswire - Tue May 19, 7:00AM CDT
Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of chronic pain, announced today that it will present at the 2015 Marcum MicroCap Conference on Thursday, May 28, 2015 in New York City at the Grand Hyatt Hotel.
Addiction Pipeline Review 2015
M2 - Thu May 14, 5:22AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mhcllx/addiction) has announced the addition of the "Addiction - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Addiction, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Addiction and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - AbbVie Inc. - Acura Pharmaceuticals, Inc. - Aradigm Corporation - Arena Pharmaceuticals, Inc. - Astraea Therapeutics, LLC - AstraZeneca PLC - Beech Tree Labs, Inc. - BioDelivery Sciences International, Inc. - Bionex Pharmaceuticals LLC - Eli Lilly and Company - Embera NeuroTherapeutics, Inc. - Euthymics Bioscience, Inc. - Foresee Pharmaceuticals, LLC - FORUM Pharmaceuticals Inc. - Gilead Sciences, Inc. - GlaxoSmithKline plc - Grunenthal GmbH - Heptares Therapeutics Ltd. - Immunovaccine, Inc. - Indivior PLC - INSYS Therapeutics, Inc. - Invion Limited - Johnson & Johnson - Pfizer Inc. - Relmada Therapeutics, Inc. - Rottapharm SpA - Royalty Pharma - Selecta Biosciences, Inc. - SK Biopharmaceuticals Co., Ltd. - Sun Pharma Advanced Research Company Ltd. - Targacept, Inc. - Zynerba Pharmaceuticals, Inc. For more information visit http://www.researchandmarkets.com/research/mhcllx/addiction
BDSI: 6.74 (+0.22), PFE: 33.24 (+0.15), LLY: 86.14 (+2.37), GSK: 40.22 (+0.06), ACUR: 2.65 (+0.14), JNJ: 95.37 (+0.29), INSY: 25.65 (+0.64), TRGT: 0.96 (-1.25), GILD: 100.65 (-0.16), AZN: 32.23 (-0.16), ABBV: 55.64 (-0.40), ARNA: 2.19 (+0.14)
